-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-09-08
Montes-Worboys and colleagues developed a dendritic-cell delivery strategy that transported fluorescently labeled amikacin into granulomas in Mycobacterium avium–infected mice. The study supports targeted localization as a potential adjunct to systemic therapy, while also showing why fluorescent conjugates, inflammatory markers, and disease-model limitations must be considered before translation.
-
Bacillus Strains Shape γ-Glutamyl Peptide Production
2026-09-07
This study systematically compares six Bacillus strains in brain heart infusion and hemoglobin hydrolysate media to determine how organism choice and substrate environment influence γ-glutamyl peptide production. Its central practical finding is that medium composition often had a stronger effect than strain identity, providing a useful framework for fermentation-based kokumi peptide production and for interpreting glutathione-related outputs.
-
Metabolomics Reveals Carbapenemase Resistance
2026-09-07
A 2025 study used LC-MS/MS metabolomics and supervised machine learning to distinguish carbapenemase-producing from non-producing Enterobacterales in antibiotic-free cultures. Its metabolite signatures provide mechanistic clues about resistance and a possible route toward faster diagnostics than conventional culture-based workflows.
-
Hypoxia and Immunometabolism in the Tumor Microenvironment
2026-09-05
This Cancer Letters review integrates tumor hypoxia, metabolic reprogramming, and immune-cell dysfunction into a feedback model of immunosuppressive tumor-microenvironment formation. Its practical value lies in showing why tumor metabolism and immune metabolism should be studied together when evaluating therapeutic strategies and redox-associated biomarkers.
-
8-Chloroadenosine for RNA Regulation Workflows
2026-09-04
8-Chloroadenosine provides a practical chemical perturbation for separating RNA production from RNA stability in cell-based experiments. This workflow links transcriptional inhibition with the RP3-340N1.2–IL-6 axis, helping researchers design stronger RNA metabolism studies and cancer research assays.
-
Bestatin and Actinonin in Myeloma Cell Proliferation
2026-09-04
The reference study separates cell-surface aminopeptidase inhibition from the antiproliferative effects of bestatin and actinonin. By using drug-efflux modifiers, it provides pharmacological evidence that intracellular exposure, regulated by MRP and P-glycoprotein, is central to inhibitor activity in U937 and K562 cells.
-
SB 431542 Workflows for ALK5 Inhibition
2026-09-04
SB 431542 is a selective ALK5 inhibitor for dissecting TGF-β/Smad2 signaling in cancer, immune, and stem-cell-derived neuronal models. This workflow-focused guide shows how to connect pathway validation with a scalable human sensory-neuron system for HSV-1 latency research while keeping compound effects distinct from neuronal and viral phenotypes.
-
Biomimetic Models of Lung Drug Permeability
2026-09-03
The reference study compares immobilised artificial membrane liquid chromatography and open-tubular capillary electrochromatography, each coupled with mass spectrometry, as biomimetic tools for modelling pulmonary drug permeability. Its findings show that the methods are complementary: IAM-LC more closely reflects conventional partitioning and permeability behavior, whereas OT-CEC provides additional information about phospholipid composition and drug–membrane interactions.
-
Self-Amplifying RNA Vaccines for Influenza
2026-09-02
A 2026 study found that low-dose self-amplifying RNA vaccines overcame a major immunogenicity problem observed with influenza B antigens in conventional mRNA formulations. In mice, trivalent saRNA generated durable antibody responses and complete protection against influenza B challenge, highlighting a dose-sparing strategy that remains to be validated beyond preclinical models.
-
From Proteomics to Signal: Validating HMGB1
2026-09-02
Translational biomarker programs must connect discovery-scale proteomics with sensitive, spatially resolved validation. This thought-leadership article examines how the FITC Goat Anti-Rabbit IgG (H+L) Antibody can strengthen HMGB1 validation workflows in diabetic nephropathy research through mechanistic signal amplification, disciplined controls, and strategic assay selection.
-
Cyanine 3 Tyramide for Neural Circuit Assays
2026-09-01
Cyanine 3 Tyramide provides localized signal amplification for low-abundance targets in neuroscience assays. This article translates recent oxytocin-circuit findings into practical IHC and ISH assay decisions while clarifying workflow limits and controls.
-
Ferrostatins, Lipid Damage, and Ferroptosis
2026-09-01
Skouta and colleagues established ferrostatin-1 as a selective inhibitor of ferroptosis that protects cells by suppressing oxidative lipid damage rather than broadly eliminating reactive oxygen species. The study connected lipid peroxidation with cell death across Huntington’s disease, periventricular leukomalacia, and kidney dysfunction models, while using mechanistic assays and analogue design to improve ferrostatin properties.
-
GW4064 and FXR: Reading Bile Acid Flux
2026-08-31
GW4064 is a non-steroidal FXR agonist that can reveal how receptor activation affects bile acid transport, barrier integrity, and lipid phenotypes. This flux-centered guide connects the compound’s pharmacology with assay decisions informed by recent cholestatic-injury research.
-
Miltefosine for Neutrophil Differentiation Workflows
2026-08-31
Miltefosine is best known as a PI3K/Akt pathway modulator, yet recent evidence positions it as a context-dependent driver of neutrophil differentiation through Ras/MEK/ERK signaling. This guide translates that finding into practical phospho-signaling, cell-function, and leukopenia-model workflows while separating established product specifications from exploratory assay recommendations.
-
EZ Cap™ Cas9 mRNA (5-moUTP) Workflow Guide
2026-08-30
Use EZ Cap™ Cas9 mRNA (5-moUTP) to build transient, guide-directed perturbation workflows for zebrafish neurodegeneration models, cultured neural cells, and translational gene therapy research. Its Cap1 structure, poly(A) tail, and 5-moUTP modification support practical experiments where expression, RNA stability, and reduced innate immune stimulation are important.